Home / Health / India's First Biosimilar Eye Drug Launched
India's First Biosimilar Eye Drug Launched
19 Feb
Summary
- Zydus Lifesciences launched Anyra, a biosimilar of Aflibercept 2 mg.
- Anyra treats neovascular AMD, DME, and other vision-impairing eye conditions.
- The drug aims to provide affordable retinal care and expand patient access.
Zydus Lifesciences has introduced Anyra, a groundbreaking biosimilar of Regeneron Pharmaceuticals' Aflibercept 2 mg, marking a significant advancement in Indian ophthalmology. This drug is specifically formulated for the treatment of various eye conditions that can lead to irreversible vision loss.
Anyra targets neovascular (wet) Age-related Macular Degeneration, visual impairment from macular edema secondary to Retinal Vein Occlusion, and Diabetic Macular Edema, among others. The company highlighted that these chronic retinal diseases affect a substantial patient population requiring consistent anti-VEGF therapy.
This indigenous development is poised to enhance affordability and ensure treatment continuity for patients who require repeated intravitreal injections over extended periods. Zydus Lifesciences aims to expand access to critical therapies, offering a more affordable solution for advanced biological treatments in retinal care.
